Abstract
Objective: The implantation of autologous bone marrow-derived cells has been used for the treatment of ischemic diseases, but obvious interindividual differences were observed in the improvement of regional perfusion and cardiac function after treatment. We examined the angiogenic potency of bone marrow cells from patients with different clinical backgrounds. Methods: Bone marrow cells were collected from 25 patients scheduled to undergo sternotomy for various surgical procedures. We examined the quality of bone marrow cells and investigated their angiogenic potency by using an ischemic limb model in mice with severe combined immunodeficiency. Results: When compared with their control cohort, bone marrow cells from patients with advanced age, renal failure, or anemia had significantly less c-kit- and CD34-positive stem cells (P <.05) and showed significantly lower vascular endothelial growth factor production and colony-forming units in culture (P <.05). Furthermore, the implantation of bone marrow cells from patients with advanced age, renal failure, or anemia into the ischemic limbs of mice also resulted in significantly worse blood flow recovery and clinical score when compared with the implantation of bone marrow cells from their control cohorts (P <.05). However, the bone marrow cells from patients with diabetes and hypertension did not show significant impairment of angiogenic potency when compared with their control cohorts. Conclusions: The quality and angiogenic potency of bone marrow cells differs among patients. Advanced age, renal failure, and anemia should be the risk factors related to poor angiogenic potency of bone marrow cells for the treatment of ischemic diseases.
| Original language | English |
|---|---|
| Pages (from-to) | 459-465 |
| Number of pages | 7 |
| Journal | Journal of Thoracic and Cardiovascular Surgery |
| Volume | 139 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Feb 2010 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Surgery
- Pulmonary and Respiratory Medicine
Cite this
Impaired angiogenic potency of bone marrow cells from patients with advanced age, anemia, and renal failure. / Li, Tao Sheng; Kubo, Masayuki; Ueda, Kazuhiro; Murakami, Masanori; Mikamo, Akihito; Hamano, Kimikazu.
In: Journal of Thoracic and Cardiovascular Surgery, Vol. 139, No. 2, 02.2010, p. 459-465.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Impaired angiogenic potency of bone marrow cells from patients with advanced age, anemia, and renal failure
AU - Li, Tao Sheng
AU - Kubo, Masayuki
AU - Ueda, Kazuhiro
AU - Murakami, Masanori
AU - Mikamo, Akihito
AU - Hamano, Kimikazu
PY - 2010/2
Y1 - 2010/2
N2 - Objective: The implantation of autologous bone marrow-derived cells has been used for the treatment of ischemic diseases, but obvious interindividual differences were observed in the improvement of regional perfusion and cardiac function after treatment. We examined the angiogenic potency of bone marrow cells from patients with different clinical backgrounds. Methods: Bone marrow cells were collected from 25 patients scheduled to undergo sternotomy for various surgical procedures. We examined the quality of bone marrow cells and investigated their angiogenic potency by using an ischemic limb model in mice with severe combined immunodeficiency. Results: When compared with their control cohort, bone marrow cells from patients with advanced age, renal failure, or anemia had significantly less c-kit- and CD34-positive stem cells (P <.05) and showed significantly lower vascular endothelial growth factor production and colony-forming units in culture (P <.05). Furthermore, the implantation of bone marrow cells from patients with advanced age, renal failure, or anemia into the ischemic limbs of mice also resulted in significantly worse blood flow recovery and clinical score when compared with the implantation of bone marrow cells from their control cohorts (P <.05). However, the bone marrow cells from patients with diabetes and hypertension did not show significant impairment of angiogenic potency when compared with their control cohorts. Conclusions: The quality and angiogenic potency of bone marrow cells differs among patients. Advanced age, renal failure, and anemia should be the risk factors related to poor angiogenic potency of bone marrow cells for the treatment of ischemic diseases.
AB - Objective: The implantation of autologous bone marrow-derived cells has been used for the treatment of ischemic diseases, but obvious interindividual differences were observed in the improvement of regional perfusion and cardiac function after treatment. We examined the angiogenic potency of bone marrow cells from patients with different clinical backgrounds. Methods: Bone marrow cells were collected from 25 patients scheduled to undergo sternotomy for various surgical procedures. We examined the quality of bone marrow cells and investigated their angiogenic potency by using an ischemic limb model in mice with severe combined immunodeficiency. Results: When compared with their control cohort, bone marrow cells from patients with advanced age, renal failure, or anemia had significantly less c-kit- and CD34-positive stem cells (P <.05) and showed significantly lower vascular endothelial growth factor production and colony-forming units in culture (P <.05). Furthermore, the implantation of bone marrow cells from patients with advanced age, renal failure, or anemia into the ischemic limbs of mice also resulted in significantly worse blood flow recovery and clinical score when compared with the implantation of bone marrow cells from their control cohorts (P <.05). However, the bone marrow cells from patients with diabetes and hypertension did not show significant impairment of angiogenic potency when compared with their control cohorts. Conclusions: The quality and angiogenic potency of bone marrow cells differs among patients. Advanced age, renal failure, and anemia should be the risk factors related to poor angiogenic potency of bone marrow cells for the treatment of ischemic diseases.
UR - http://www.scopus.com/inward/record.url?scp=74649083695&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=74649083695&partnerID=8YFLogxK
U2 - 10.1016/j.jtcvs.2009.07.053
DO - 10.1016/j.jtcvs.2009.07.053
M3 - Article
C2 - 19748631
AN - SCOPUS:74649083695
VL - 139
SP - 459
EP - 465
JO - Journal of Thoracic and Cardiovascular Surgery
JF - Journal of Thoracic and Cardiovascular Surgery
SN - 0022-5223
IS - 2
ER -